Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300…
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its…
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…
WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health…
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the…
"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ --…
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in…
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in…
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE…
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE…